Bavachin protects against diet-induced hepatic steatosis and obesity in mice

Wang, Xiang; Li, Lin; Yuan, Qianqian; Wang, Xiuyun; Zhang, Qing; Zhang, Xiaomin; Tang, Ke-chao; Guo, Manyu; Dong, Ting-yu; Han, Weixing; Huang, Dake; Qi, Yinliang; Zhang, Mei; Zhang, Huabing

doi:10.1038/s41401-023-01056-z

Cited by 11 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In response to lipid accumulation, VDAC exhibits a reduction in GSK3-mediated phosphorylation, modulating the permeability of the outer mitochondrial membrane. This allows a large influx of water and calcium into the mitochondria, leading to organelle edema as well as the release of cyt C that eventually induces cell death [ 67 , 68 ]. Furthermore, in PA-mediated lipotoxicity, the mitochondrial protein Sab interacts with JNK, leading to impairment of the mitochondrial electron respiratory chain, increased ROS production, and ultimately activation of apoptosis [ 69 ].…”

Section: Lipotoxicity In Masldmentioning

confidence: 99%

Updated mechanisms of MASLD pathogenesis

Li,

Yang,

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) has garnered considerable attention globally. Changing lifestyles, over-nutrition, and physical inactivity have promoted its development. MASLD is typically accompanied by obesity and is strongly linked to metabolic syndromes. Given that MASLD prevalence is on the rise, there is an urgent need to elucidate its pathogenesis. Hepatic lipid accumulation generally triggers lipotoxicity and induces MASLD or progress to metabolic dysfunction-associated steatohepatitis (MASH) by mediating endoplasmic reticulum stress, oxidative stress, organelle dysfunction, and ferroptosis. Recently, significant attention has been directed towards exploring the role of gut microbial dysbiosis in the development of MASLD, offering a novel therapeutic target for MASLD. Considering that there are no recognized pharmacological therapies due to the diversity of mechanisms involved in MASLD and the difficulty associated with undertaking clinical trials, potential targets in MASLD remain elusive. Thus, this article aimed to summarize and evaluate the prominent roles of lipotoxicity, ferroptosis, and gut microbes in the development of MASLD and the mechanisms underlying their effects. Furthermore, existing advances and challenges in the treatment of MASLD were outlined.

show abstract

Section: Lipotoxicity In Masldmentioning

confidence: 99%

Updated mechanisms of MASLD pathogenesis

Li,

Yang,

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…Aqueous extracts from Scolymus hispanicus L. (golden thistle) as well as Bee bread from Heterotrigona itama can also elevate hepatic glycogen reserves reduced by a high-fat diet [337,338]. Bavachin, a flavonoid isolated from the seeds and fruits of Psoralea corylifolia L., significantly increased the phosphorylation level of GSK3β in mouse primary hepatocytes and Huh 7 cells, which led to an increase in glycogen synthesis and improved insulin resistance [295]. The combined treatment of genistein, a natural phytoestrogen, or chlorogenic acid, a phenolic compound commonly found in many foods and herbs, with metformin, respectively, ameliorated MAFLD, which was partially achieved by upregulating GSK-3β phosphorylation levels and thereby enhancing glycogen synthesis [296,297].…”

Section: Natural Products and Glycogen Metabolism In Mafldmentioning

confidence: 99%

Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective

Fu,

Wang,

Qin

2024

Metabolites

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MAFLD), characterized primarily by hepatic steatosis, has become the most prevalent liver disease worldwide, affecting approximately two-fifths of the global population. The pathogenesis of MAFLD is extremely complex, and to date, there are no approved therapeutic drugs for clinical use. Considerable evidence indicates that various metabolic disorders play a pivotal role in the progression of MAFLD, including lipids, carbohydrates, amino acids, and micronutrients. In recent years, the medicinal properties of natural products have attracted widespread attention, and numerous studies have reported their efficacy in ameliorating metabolic disorders and subsequently alleviating MAFLD. This review aims to summarize the metabolic-associated pathological mechanisms of MAFLD, as well as the natural products that regulate metabolic pathways to alleviate MAFLD.

show abstract

“…8-MOP, a potential ligand of VDR [42] , mitigates hepatic steatosis by suppressing insulin substrate-1 (IRS1) signaling and increasing insulin substrate-2 (IRS2) expression, thereby downregulating downstream de novo lipogenesis due to VD deficiency in Sprague-Dawley (SD) rats [43] . Wei et al [44] demonstrated that Bavachin (BV) exhibited significant therapeutic benefits in both HFD-induced NAFLD mouse models and PA/oleic acid (PA/OA)-stimulated mouse primary hepatocytes and Huh cell models. Liver RNA-seq was employed to elucidate the underlying mechanisms, followed by real-time fluorescence quantitative PCR (qPCR) analysis to validate these mechanisms.…”

Section: Amelioration Of Hepatic Steatosis and Nonalcoholic Fatty Liv...mentioning

confidence: 99%

Dual effects of Psoraleae Fructus on the liver: hepatoprotection or hepatoxicity?

Tang,

Yu,

et al. 2024

Acupuncture and Herbal Medicine

View full text Add to dashboard Cite

Psoraleae Fructus, the dried mature fruit of the leguminous plant Psoralea corylifolia L., contains flavonoids, coumarins, monoterpene phenols, and benzofurans. It exhibits various pharmacological activities, including immune regulation, antioxidant properties, photosensitivity, and estrogen-like effects, and finds extensive use in the clinical treatment of osteoporosis, vitiligo, and psoriasis. Extensive pharmacological research has demonstrated that Psoraleae Fructus and its components improve liver function and protect hepatocytes in animal and cellular models of liver diseases. Moreover, with the increasing clinical applications of Psoraleae Fructus and its derivatives, as well as the progression in adverse drug reaction surveillance, there is an increase in clinical cases involving these preparations and the enhancement of monitoring for any adverse reactions linked to Psoraleae Fructus and its related compounds. Here, we examined the hepatoprotective effects and hepatotoxicity of the monomer components, extracts, and related preparations of Psoraleae Fructus. We aim to contribute to safety evaluation, facilitate informed clinical application, and foster advancements in Psoraleae Fructus and its derivatives.

show abstract

Bavachin protects against diet-induced hepatic steatosis and obesity in mice

Cited by 11 publications

References 44 publications

Updated mechanisms of MASLD pathogenesis

Updated mechanisms of MASLD pathogenesis

Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective

Dual effects of Psoraleae Fructus on the liver: hepatoprotection or hepatoxicity?

Contact Info

Product

Resources

About